Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study (cid:1)
暂无分享,去创建一个
W. Ageno | M. Vinceti | F. Santilli | V. Poletti | L. Carrozzi | E. Grandone | S. Costanzo | A. Castelnuovo | F. Gianfagna | L. Iacoviello | A. Antinori | A. Mengozzi | J. Milic | M. Meschiari | C. Mussini | G. Guaraldi | A. Agodi | A. Cingolani | F. Cipollone | A. Rognoni | G. Patti | R. Marcucci | M. Mennuni | S. Marongiu | R. Vettor | C. Signorelli | F. Cacciatore | R. Pesavento | F. Aucella | A. Odone | L. Blandi | A. Bartoloni | M. Mapelli | P. Agostoni | A. Vianello | C. Torti | M. Bonaccio | L. Menicanti | F. Minutolo | F. Fusco | A. Cascio | P. Bonfanti | E. Pasi | R. Cauda | R. Arboretti | S. Maitan | I. Gentile | Pasquale Abete | M. Mazzitelli | M. Fantoni | N. Berselli | G. Parruti | A. Vergori | L. Aiello | G. Barbieri | L. Caiano | C. Colomba | F. Crosta | G. Danzi | G. Guarnieri | G. Larizza | A. Leone | G. Maccagni | R. Maragna | G. Maresca | C. Marotta | L. Marra | F. Mastroianni | F. Menichetti | A. Montineri | M. Musso | M. Olivieri | Francesco Petri | B. Pinchera | C. Ravaglia | M. Rossato | V. Sangiovanni | C. Sanrocco | L. Scorzolini | R. Sgariglia | P. Simeone | M. Astuto | Ardes | B. Molena | A. Ciccullo | E. Taddei | G. Tano | R. Parisi | R. Caterina | C. Colombo | F. Gennaro | A. Virano | K. Donati | S. Mancarella | E. Graziani | Laura Vocciante | M. Rossi | S. A. Moghazi | D. Damiano | Ferruccio Madaro | Daniela Niola | Antonella Palimodde
[1] H. Billett,et al. Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality , 2020, Thrombosis and Haemostasis.
[2] M. Narasimhan,et al. Association of anticoagulation dose and survival in hospitalized COVID‐19 patients: A retrospective propensity score‐weighted analysis , 2020, European journal of haematology.
[3] M. Massari,et al. Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study , 2020, EClinicalMedicine.
[4] Noor A. Jatoi,et al. Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine , 2020, Thrombosis and Haemostasis.
[5] D. Centonze,et al. SARS-CoV-2 Transmission and Outcome in Neuro-rehabilitation Patients Hospitalized at Neuroscience Hospital in Italy , 2020, Mediterranean journal of hematology and infectious diseases.
[6] Benjamin S. Glicksberg,et al. Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19 , 2020, Journal of the American College of Cardiology.
[7] R. de Caterina,et al. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study , 2020, European Journal of Internal Medicine.
[8] A. Combes,et al. Heparin-induced thrombocytopenia in COVID-19 patients with severe acute respiratory distress syndrome requiring extracorporeal membrane oxygenation: two case reports , 2020, Journal of Artificial Organs.
[9] R. de Caterina,et al. Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study , 2020, Nutrition, Metabolism and Cardiovascular Diseases.
[10] C. Gazzaruso,et al. Association between antithrombin and mortality in patients with COVID-19. A possible link with obesity , 2020, Nutrition, Metabolism and Cardiovascular Diseases.
[11] P. Prandoni,et al. The hazard of (sub)therapeutic doses of anticoagulants in non‐critically ill patients with Covid‐19: The Padua province experience , 2020, Journal of Thrombosis and Haemostasis.
[12] K. Chung,et al. DoD COVID-19 Practice Management Guide: Clinical Management of COVID-19 , 2020 .
[13] S. Ayis,et al. The association between treatment with heparin and survival in patients with Covid-19 , 2020, Journal of Thrombosis and Thrombolysis.
[14] W. Oh,et al. Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study , 2020, Blood.
[15] R. de Caterina,et al. Controversial Relationship between Renin-Angiotensin System Inhibitors and Severity of COVID-19: Announcing a Large Multicentre Case-Control Study in Italy. , 2020, HYPERTENSION.
[16] V. Fuster,et al. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19 , 2020, Journal of the American College of Cardiology.
[17] M. Cattaneo,et al. Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial. , 2020, Blood transfusion = Trasfusione del sangue.
[18] S. Birocchi,et al. Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified? , 2020, Thrombosis and Haemostasis.
[19] M. Ramakers,et al. High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients , 2020, Journal of Thrombosis and Haemostasis.
[20] E. Grandone,et al. Pulmonary thrombosis in 2019‐nCoV pneumonia? , 2020, Journal of Thrombosis and Haemostasis.
[21] C. Beigelman-Aubry,et al. Pulmonary embolism in patients with COVID-19: Time to change the paradigm of computed tomography , 2020, Thrombosis Research.
[22] W. Liang,et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19 , 2020, The Lancet Haematology.
[23] W. Ageno,et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). , 2020, Blood transfusion = Trasfusione del sangue.
[24] G. Lippi,et al. D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis , 2020, Thrombosis and Haemostasis.
[25] G. Danzi,et al. Acute pulmonary embolism and COVID-19 pneumonia: a random association? , 2020, European heart journal.
[26] Dengju Li,et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.
[27] A. Falanga,et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.
[28] Dengju Li,et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.
[29] P. Lingamaneni,et al. Heparin-Induced Thrombocytopenia in COVID-19 , 2020, Journal of investigative medicine high impact case reports.
[30] World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance , 2020 .
[31] Tyler J. VanderWeele,et al. Sensitivity Analysis in Observational Research: Introducing the E-Value , 2017, Annals of Internal Medicine.
[32] Lena Osterhagen,et al. Multiple Imputation For Nonresponse In Surveys , 2016 .
[33] D. Meier,et al. Methods for constructing and assessing propensity scores. , 2014, Health services research.
[34] C. Cerletti,et al. Parnaparin, a low-molecular-weight heparin, prevents P-selectindependent formation of platelet-leukocyte aggregates in human whole blood , 2007, Thrombosis and Haemostasis.
[35] C. Cerletti,et al. Prevention of platelet-polymorphonuclear leukocyte interactions: new clues to the antithrombotic properties of parnaparin, a low molecular weight heparin. , 2005, Haematologica.
[36] David V Glidden,et al. Modelling clustered survival data from multicentre clinical trials , 2004, Statistics in medicine.